1. Home
  2. CTSO vs IPSC Comparison

CTSO vs IPSC Comparison

Compare CTSO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • IPSC
  • Stock Information
  • Founded
  • CTSO 1997
  • IPSC 2019
  • Country
  • CTSO United States
  • IPSC United States
  • Employees
  • CTSO N/A
  • IPSC N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • IPSC Medicinal Chemicals and Botanical Products
  • Sector
  • CTSO Health Care
  • IPSC Health Care
  • Exchange
  • CTSO Nasdaq
  • IPSC Nasdaq
  • Market Cap
  • CTSO 58.6M
  • IPSC 49.1M
  • IPO Year
  • CTSO N/A
  • IPSC 2021
  • Fundamental
  • Price
  • CTSO $0.92
  • IPSC $0.56
  • Analyst Decision
  • CTSO Buy
  • IPSC Strong Buy
  • Analyst Count
  • CTSO 2
  • IPSC 5
  • Target Price
  • CTSO $5.50
  • IPSC $3.33
  • AVG Volume (30 Days)
  • CTSO 78.2K
  • IPSC 699.1K
  • Earning Date
  • CTSO 11-06-2025
  • IPSC 11-04-2025
  • Dividend Yield
  • CTSO N/A
  • IPSC N/A
  • EPS Growth
  • CTSO N/A
  • IPSC N/A
  • EPS
  • CTSO N/A
  • IPSC N/A
  • Revenue
  • CTSO $36,107,520.00
  • IPSC $114,128,000.00
  • Revenue This Year
  • CTSO $11.93
  • IPSC $1,589.94
  • Revenue Next Year
  • CTSO $21.22
  • IPSC N/A
  • P/E Ratio
  • CTSO N/A
  • IPSC N/A
  • Revenue Growth
  • CTSO 20.18
  • IPSC 5491.77
  • 52 Week Low
  • CTSO $0.71
  • IPSC $0.34
  • 52 Week High
  • CTSO $1.61
  • IPSC $1.83
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 45.35
  • IPSC 58.62
  • Support Level
  • CTSO $0.90
  • IPSC $0.48
  • Resistance Level
  • CTSO $0.96
  • IPSC $0.62
  • Average True Range (ATR)
  • CTSO 0.05
  • IPSC 0.03
  • MACD
  • CTSO -0.00
  • IPSC 0.01
  • Stochastic Oscillator
  • CTSO 16.67
  • IPSC 57.65

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Share on Social Networks: